Initiated Buy X

MORF Morphic

Citigroup

$46

Downgrades Buy Hold X

MORF Morphic

Stifel

$69 $61

Initiated Buy X

MORF Morphic

Stifel

$44

Initiated Outperform X

MORF Morphic

SVB Leerink

$45

Initiated Buy X

MORF Morphic

Canaccord Genuity

$68

Initiated Buy X

MORF Morphic

BTIG Research

$64

Initiated Overweight X

MORF Morphic

Wells Fargo

$81

Initiated Outperform X

MORF Morphic

BMO Capital Markets

$30

Initiated Outperform X

MORF Morphic

Cowen

Initiated Buy X

MORF Morphic

Jefferies

Initiated Outperform X

MORF Morphic

Wells Fargo

MORF  Morphic Holding, Inc.

Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.